Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.
Past Team (2)Update
Milepost Ventures, previously Viridian Capital, was a venture capital firm specializing in...
Hambrecht & Quist Capital Management, LLC (HQCM), a registered investment adviser based in...
Wound down in 2006
Integra Ventures seek investments in Life Science companies in three principal areas: Drug...
Avici Systems provides professional applications for business and educational users on emerging...
Venture Capital Firm
U.S. Venture Partners (USVP) is a leading Silicon valley-based venture capital firm, helping...
Financial Service Provider
One Corporate Drive
South San Francisco, CA 94080